NewzPrediction markets Kalshi and Polymarket have faced criticism for allowing wagers on the outcomes of clinical trials. Critics, including researchers, have expressed concerns that these betting platforms could incentivize insider trading and potentially interfere with the drug development process.
In-depth summary · AI, neutralKalshi and Polymarket bets on clinical trials criticized as 'ghastly'
How the coverage differs
Same story, different emphasis — here's what each outlet chose to lead with.
NPR News (National) (US)
Balances ethical concerns from researchers with platform justifications